Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | CA4 | P22748 | 4/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | CA6 | P23280 | 3/20 | 0.52 |
| ▸ | CA5A | P35218 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27558453 | 0.83 | CA12 (0.47) | CA1CA2CA4CA9CA12 | |
| SCHEMBL2964276 | 0.83 | CA2 (0.68) | CA1CA2CA4CA9CA12 | |
| SCHEMBL31265318 | 0.80 | CA1 (0.54) | CA1CA2CA4CA9CA12 | |
| SCHEMBL8023017 | 0.80 | NPC1 (0.46) | CA1CA2CA4CA9CA12 | |
| SCHEMBL30687380 | 0.80 | NPC1 (0.46) | CA1CA2CA4CA9CA12 | |
| SCHEMBL9562238 | 0.79 | CYP2C9 (0.47) | CA1CA2CA4CA9CA12 | |
| SCHEMBL4347732 | 0.79 | TSHR (0.47) | CA1CA2CA4CA9CA12 | |
| SCHEMBL9376383 | 0.77 | KDM1A (0.42) | CA1CA2CA4CA9CA12 | |
| SCHEMBL5133404 | 0.76 | ALDH1A1 (0.65) | ALDH1A1NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL671916 | 0.76 | CA1 (0.50) | CA1CA2CA4CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118980726-A | Preparation method of composite material of modified electrode, construction of portable immunosensor and application of composite material in detection of sulfamethoxazole | 江西农业大学 | 2024-11-19 | — | — | CN | disclosed |
| EP-2590938-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | Metasignal Therapeutics Inc. (CA) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012021963-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2012-02-23 | — | — | WO | disclosed |
| EP-1618094-B1 | SUBSTITUTED HETEROARYLS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INST FOR PHARM DISCOVERY INC (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1618094-A1 | SUBSTITUTED HETEROARYLS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | The Institutes for Pharmaceutical Discovery, LLC (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050009817-A1 | Substituted heteroaryls | INSTITUTES FOR PHARMACEUTICAL DISCOVERY, L.L.C. | 2005-01-13 | — | — | US | disclosed |
| WO-2004099159-A1 | SUBSTITUTED HETEROARYLS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-0539530-A4 | PURIFICATION DIRECTED CLONING OF PEPTIDES. | — | 1993-09-15 | — | — | EP | disclosed |
| EP-0539530-A1 | PURIFICATION DIRECTED CLONING OF PEPTIDES | BIONEBRASKA, INC. (US) | 1993-05-05 | — | — | EP | disclosed |
| WO-1992001707-A1 | PURIFICATION DIRECTED CLONING OF PEPTIDES | BIONEBRASKA, INC. (US) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009817-A1 | Substituted heteroaryls | PTPRS, PTPRO, PTPRR | CA1 4632/4885CA2 4281/4885CA4 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.